Barclays’s ImmuCell ICCC Stock Holding History

Barclays’s Portfolio ICCC Stock Details ICCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$302	Buy	+30	New	+$265	﹤0.01%	5065
2025 Q4	–	Sell	-7	Closed	-$44	–	5427
2025 Q3	$44	Buy	+7	New	+$44	﹤0.01%	5322

Other funds holding ICCC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Steadtrust Allen, Texas $198M AUM 99.37% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Barclays's ICCC Position: Q2 2026 in Review

Barclays opened a new position in ImmuCell (ICCC) in Q2 2026: 30 shares worth $302. The stake represents ﹤0.01% of the portfolio and ranks #5065 among its holdings. This is a return to the name: Barclays previously reported a position in ICCC as recently as Q3 2025.

Barclays first reported a position in ICCC in Q3 2025 and has held it in 2 quarters since. 31 funds tracked by Wall St. Rank hold ICCC as of Q2 2026.

Barclays held 30 shares of ImmuCell worth $302 as of Q2 2026.
ImmuCell was a new Barclays position in Q2 2026.
ImmuCell made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5065 holding.
Barclays first reported a position in ImmuCell in Q3 2025 and has held it in 2 quarters since.
31 funds tracked by Wall St. Rank held ImmuCell as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.